Press releases

LUMICKS announced today that two major centers of excellence in cancer immunology, Fred Hutchinson Cancer Research Center and Oxford University, have adopted the z-Movi Cell Avidity Analyzer instrument for the development of promising immunotherapeutic strategies.

We are pleased to announce key appointments to our Scientific Advisory Board, with both new members strategically selected to help support our growth strategy.

Jos Maas joins as new general manager of Dynamic Single Molecule business and Geerte Hesen joins as new General Counsel. They both bring strong managerial acumen and a track record of supporting innovation.

We are excited to announnce that Joshua Young will join our leadership team to lead the company’s Investor Relations, Communications and Strategy functions.

We are pleased to announce two key appointments to our Board of Directors that bring a combined 40 years of executive-level experience in human resources and finance. Melissa McLaughlin and Solange Glaize are the newest addition to LUMICKS Board, each offering invaluable insight that will help pave the way for…

We are pleased to announce the appointment of Dr. Paul Wheeler to its leadership team, effective July 1, 2021. In the newly-created position of Chief Commercial Officer, Dr. Wheeler will lead LUMICKS aggressive commercial growth strategy by building a stronger market presence, developing highly-effective sales teams, and focusing on enhanced…

We're proud to announce ithe installation of a C-Trap® Optical Tweezers – Fluorescence & Label-free Microscopy system at VIB, the life sciences research institute in Flanders, Belgium. The C-Trap will support the research efforts of six VIB research groups across three Belgian universities studying processes underlying neurodegenerative disorders.